scholarly journals Heart failure with preserved ejection fraction diagnostic scores in an Asian population

2020 ◽  
Vol 22 (9) ◽  
pp. 1737-1739 ◽  
Author(s):  
Wouter Ouwerkerk ◽  
Jasper Tromp ◽  
Xuanyi Jin ◽  
Fazlur Jaufeerally ◽  
Poh Shuan Daniel Yeo ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Asian Population ◽  
Preserved Ejection Fraction ◽  
Diagnostic Scores

scholarly journals Cornell product is an ECG marker of heart failure with preserved ejection fraction

Heart Asia ◽  
2019 ◽  
Vol 11 (1) ◽  
pp. e011108 ◽  
Author(s):  
Eugene SJ Tan ◽  
Siew Pang Chan ◽  
Chang Fen Xu ◽  
Jonathan Yap ◽  
Arthur Mark Richards ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Asian Population ◽  
Composite Endpoint ◽  
Left Ventricular ◽  
Healthy Controls ◽  
Preserved Ejection Fraction ◽  
S Wave ◽  
All Cause Mortality ◽  
Cornell Product

ObjectiveECG markers of heart failure (HF) with preserved ejection fraction (HFpEF) are lacking. We hypothesised that the Cornell product (CP) is a risk marker of HFpEF and has prognostic utility in HFpEF.MethodsCP =[(amplitude of R wave in aVL+depth of S wave in V3)×QRS] was measured on baseline 12-lead ECG in a prospective Asian population-based study of 606 healthy controls (aged 55±10 years, 45% men), 221 hypertensive controls (62±9 years, 58% men) and 242 HFpEF (68±12 years, 49% men); all with EF ≥50% and followed for 2 years for all-cause mortality and HF hospitalisations.ResultsCP increased across groups from healthy controls to hypertensive controls to HFpEF, and distinguished between HFpEF and hypertension with an optimal cut-off of ≥1800 mm*ms (sensitivity 40%, specificity 85%). Age, male sex, systolic blood pressure (SBP) and heart rate were independent predictors of CP ≥1800 mm*ms, and CP was associated with echocardiographic E/e′ (r=0.27, p<0.01) and left ventricular mass index (r=0.46, p<0.01). Adjusting for clinical and echocardiographic variables and log N-terminal pro B-type natriuretic peptide (NT-proBNP), CP ≥1800 mm*ms was significantly associated with HFpEF (adjusted OR 2.7, 95% CI 1.0 to 7.0). At 2-year follow-up, there were 29 deaths and 61 HF hospitalisations, all within the HFpEF group. Even after adjusting for log NT-proBNP, clinical and echocardiographic variables, CP ≥1800 mm*ms remained strongly associated with a higher composite endpoint of all-cause mortality and HF hospitalisations (adjusted HR 2.1, 95% CI 1.2 to 3.5).ConclusionThe Cornell product is an easily applicable ECG marker of HFpEF and predicts poor prognosis by reflecting the severity of diastolic dysfunction and LV hypertrophy.

scholarly journals Evaluation of 2 Existing Diagnostic Scores for Heart Failure With Preserved Ejection Fraction Against a Comprehensively Phenotyped Cohort

Circulation ◽  
2021 ◽  
Vol 143 (3) ◽  
pp. 289-291
Author(s):  
Timothy W. Churchill ◽  
Shawn X. Li ◽  
Lisa Curreri ◽  
Emily K. Zern ◽  
Emily S. Lau ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Preserved Ejection Fraction ◽  
Diagnostic Scores

Diagnostic scores predict morbidity and mortality in patients hospitalized for heart failure with preserved ejection fraction

2021 ◽  
Author(s):  
Frederik H. Verbrugge ◽  
Yogesh N.V. Reddy ◽  
Hidemi Sorimachi ◽  
Kazunori Omote ◽  
Rickey E. Carter ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Morbidity And Mortality ◽  
Preserved Ejection Fraction ◽  
Diagnostic Scores

Acute heart failure with preserved ejection fraction and long-term Readmisions

2008 ◽  
Vol 7 ◽  
pp. 62-63
Author(s):  
J NUNEZ ◽  
L MAINAR ◽  
G MINANA ◽  
R ROBLES ◽  
J SANCHIS ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Acute Heart Failure ◽  
Preserved Ejection Fraction

Galectin-3 in Heart Failure – Linking Fibrosis, Remodelling and Progression

2010 ◽  
Vol 6 (2) ◽  
pp. 33 ◽  
Author(s):  
Christopher R deFilippi ◽  
G Michael Felker ◽  
◽  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Risk Stratification ◽  
Cardiac Fibrosis ◽  
The Elderly ◽  
Preserved Ejection Fraction ◽  
Heart Failure Patients ◽  
Large Populations ◽  
Galectin 3

For many with heart failure, including the elderly and those with a preserved ejection fraction, both risk stratification and treatment are challenging. For these large populations and others there is increasing recognition of the role of cardiac fibrosis in the pathophysiology of heart failure. Galectin-3 is a novel biomarker of fibrosis and cardiac remodelling that represents an intriguing link between inflammation and fibrosis. In this article we review the biology of galectin-3, recent clinical research and its application in the management of heart failure patients.

Sign in / Sign up

Export Citation Format

Share Document